USP51 and neoplasm: Upon depletion of USP51, TWIST1 is polyubiquitinated and subsequently degraded by the proteasome, resulting in a decrease in NSCLC cell stemness and in vivo inhibition of tumor growth (Fig. 9); these finding suggest that USP51 could be a candidate therapeutic target for NSCLC.